Table 2 Main characteristics of the effective sample (n = 157)
All patients (n = 157) | Without LVDD (n = 55) | With LVDD (n = 102) | |
|---|---|---|---|
Males, n (%) | 88 (56.1) | 28 (50.9) | 60 (58.8) |
Age, mean (SD) | 63 (10) | 58 (11) | 65 (9) |
Caucasian, n (%) | 142 (90.4) | 48 (87.3) | 94 (92.1) |
HT duration (months), mean (SD) | 120 (104) | 47 (53) | 160 (104) |
Resistant HT, n (%) | 117 (74.5) | 41 (74.5) | 76 (74.5) |
Obesity, n (%) | 82 (52.2) | 31 (56.4) | 51 (50.0) |
Diabetes Mellitus, n (%) | 81 (51.6) | 28 (52.8) | 53 (51.9) |
Dyslipidaemia, n (%) | 133 (84.7) | 47 (85.5) | 86 (84.3) |
CKD, n (%) | 49 (31.2) | 12 (21.8) | 37 (36.3) |
Stroke, n (%) | 36 (22.9) | 13 (23.6) | 23 (22.5) |
COPD, n (%) | 20 (12.7) | 5 (9.1) | 15 (14.7) |
OSA, n (%) | 31 (19.7) | 8 (14.5) | 23 (22.5) |
Smoker, n (%) | 34 (21.7) | 6 (10.9) | 28 (27.5) |
Alcoholic, n (%) | 16 (10.8) | 6 (10.9) | 10 (98.0) |
N° of AHT drugs, median (min-max) | 4 (1–7) | 4 (1–7) | 4 (1–6) |
SBP (mmHg), median (P25-P75) | 131 (122–142) | 124 (118–135) | 133 (126–144) |
DBP (mmHg), median (P25-P75) | 78 (72–84) | 78 (73–84) | 77 (72–84) |
MBP (mmHg), median (P25-P75) | 91 (85–99) | 91 (84–96) | 92 (85–101) |
HR (bpm), median (P25-P75) | 63 (57–70) | 66 (60–74) | 62 (56–69) |
SVI (ml/m2), median (P25-P75) | 43 (35–51) | 37 (31–45) | 46 (39–54) |
CI (l/min/m2), median (P25-P75) | 2.7 (2.4–3.1) | 2.6 (2.3–2.8) | 2.8 (2.5–2.4) |
LCWI (kg.m/m2), median (P25-P75) | 3.3 (2.7–3.8) | 3.1 (2.6–3.5) | 3.4 (2.9–4.4) |
SVRI (dyne.s.cm5/m2), median (P25-P75) | 2599 (2212–3083) | 2797 (2477–3185) | 2472 (2142–2922) |
VI (1/1000/s), median (P25-P75) | 39 (31–48) | 36 (29–44) | 40 (31–49) |